• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Exonate launches diabetic macular oedema trial pharmatimes
    February 04, 2021
    Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service